Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities

References

• Creech OJ, Jr, Krementz ET, Ryan RF, Winbald JN. Chemtherapy of cancer: Regional perfusion utilizing an extracorporal circuit. Ann Surg 1958; 148: 616–632
   PubMed Web of Science ®Google Scholar
• Hohenberger W. Isolation perfusion for malignant melanomas: Established facts and parameters to be clarified. Progress in regional cancer therapy, R Jakesz, H Rainer. Springer, Berlin, Heidelberg, New York 1990; 182
   Google Scholar
• Meyer T, Göhl J, Haas C, Hohenberger W. Hyperthermic isolated limb perfusion–23 years’ experience and improvement of results by modification of technique. Onkologie 1998; 21: 198–202
   Google Scholar
• Smith JL. Histopathology and biological behaviour of melanoma. Neoplasms of skin and malignant melanoma, JL Smith. Year Book Medical Publishers, Chicago 1976; 293
   Google Scholar
• Knorr C, Meyer T, Janssen T, Goehl J, Hohenberger W. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 2006; 32: 224–227
   PubMed Web of Science ®Google Scholar
• Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905–910
   PubMedGoogle Scholar
• Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Sanders G, Cheng TY, Pruitt SK, Seigler H, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008; 15: 2195–2205
   PubMed Web of Science ®Google Scholar
• Lienard D, Eggermont AM, Kroon BR, Koops HS, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: Indications and results. Semin Surg Oncol 1998; 14: 202–209
   PubMedGoogle Scholar
• Lienard D, Lejune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-γ and melphalan in isolation perfusion. World J Surg 1992; 16: 234–240
   PubMed Web of Science ®Google Scholar
• Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A, Persiani L, Santinami M, Santoro N, Cascinelli N. Treatment of primari or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon and melphalan. Cancer 1994; 73: 483–492
   PubMed Web of Science ®Google Scholar
• Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM, 3rd, Alexander HR, et al. American College of Surgeons Oncology Group Trial Z0020. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196–4201
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Cavaliere F, Garinei R, Anzà M, Di Angelo P, Psaila A, Piarulli L, Callopoli A, Bruno P, Di Filippo S, et al. TNFα-based isolated hyperthermic limb perfusion (HILP) in the treatment of limb recurerent melanoma: Update 16 years after its first clinical application. J Chemother 2004; 16: S62–65
   PubMed Web of Science ®Google Scholar
• Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002; 29: 400–409
   PubMedGoogle Scholar
• Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903–907
   PubMed Web of Science ®Google Scholar
• Krementz ET, Sutherland CM, Muchmore JH. Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am 1996; 76: 1313–1330
   PubMedGoogle Scholar
• Di Filippo F, Calabrò A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F, Cavaliere R. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63: 2551–2561
   PubMed Web of Science ®Google Scholar
• Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer 2000; 89: 1983–1991
   PubMed Web of Science ®Google Scholar
• Pace M, Gattai R, Matteini M, Mascitelli EM, Bechi P. Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma: The experience of the Tuscan Reference Centre. J Exp Clin Cancer Res 2008; 27: 67
   PubMedGoogle Scholar
• Knorr C, Melling N, Goehl J, Drachsler T, Hohenberger W, Meyer T. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP). Int J Hyperthermia 2008; 24: 409–414
   PubMed Web of Science ®Google Scholar
• Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Göhl J, Eggermont AM, Di Filippo F, Krementz ET, Ruiter D, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906–2912
   PubMed Web of Science ®Google Scholar